CPA
LFCR icon

Capital Performance Advisors’s Lifecore Biomedical LFCR Stock Holding History

Capital Performance Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$10 – 1534
2024
Q3 		$10 Buy
+2
New +$10 ﹤0.01% 2882

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital Performance Advisors's LFCR Position: Q4 2024 in Review

Capital Performance Advisors sold out of Lifecore Biomedical (LFCR) in Q4 2024, closing a stake of 2 shares — an estimated $10 sold.

Capital Performance Advisors first reported a position in LFCR in Q3 2024 and held it in 1 quarter. The position peaked at $10 in Q3 2024. 77 funds tracked by Wall St. Rank hold LFCR as of Q4 2024.

  • Capital Performance Advisors reported no remaining Lifecore Biomedical position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Lifecore Biomedical shares in Q4 2024, an estimated $10.
  • Capital Performance Advisors first reported a position in Lifecore Biomedical in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Lifecore Biomedical position peaked at $10 in Q3 2024.
  • 77 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.